The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.
Patient advocacy groups in North Carolina, like ACSCAN, are demanding that the state should implement the oral/infusion cancer drug parity law. While Oregon was the first state to pass the law in 2008, 39 states and the District of Columbia have followed suit. Today, North Carolina is one of 11 states where insurers demand higher out-of-pocket costs from patients on oral anticancer agents, compared with those who get infusions or injections.
“It should not matter what method of chemotherapy a cancer patient is receiving, whether it’s an IV infusion or a pill,” said Christine Weason, the North Carolina government relations director for the American Cancer Society Cancer Action Network in an interview. “It’s just about fairness.” A bill to this effect, passed in the North Carolina House in April this year, is currently pending in the Senate.
Read more in The Charlotte Observer.
Watch a panel discussion among payers and healthcare policy experts on the topic that was recently convened by AJMC.
Read more here: http://www.charlotteobserver.com/living/health-family/article27365617.html#storylink=cpy
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More